Zai Lab announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics. MediLink is an innovative drug development company focusing on next generation anti-body-drug conjugates and related technologies. Through this collaboration, the company has expanded its lung cancer franchise and global oncology pipeline with YL212, a novel DLL3 ADC program. Under the terms of the agreement, MediLink will be eligible to receive certain upfront fees and development and sales-based milestone payments as well as tiered royalties on global annual net sales and potential third-party sublicensing payments. Zai Lab will be responsible for all the development and commercialization activities globally.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ZLAB:
- Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
- Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
- Zai Lab to highlight new data from oncology portfolio at 2023 AACR meeting
- Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
